|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
NSAIDS CONCURRENT ADMINISTRATION SHOULD BE CAUTIOUS AS THESE INHIBIT PROSTAGLANDIN SECRETIONS WHICH MAY REDUCE THE EFFECT OF THE DRUG
|
CO-ADMINISTRATION OF NSAIDS WITH A QUINOLONES MAY INCREASE THE RIKS OF CNS STIMULATION AND CONVULSIONS; THIS INTERACTION HAS NOT BEEN OBSERVED WITH MOXIFLOXACIN CLINICAL AND PRECLINICAL TRIALS
|
CO-ADMINISTRATION MAY INTERFERE WITH THE BENEFITS OF ASPIRIN TAKEN FOR HEART DISEASE, SHOULD BE TAKEN ON DIFFERENT TIMES
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH THIAZIDES MAY RESULT IN REDUCED NATRIURETIC EFFECT OF THIAZIDE DIURETICS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF CELECOXIB WITH DRUGS KNOWN TO INHIBIT CYP4502C9, SUCH AS AMIODARONE, MAY RESULT IN INCREASED PLASMA CONCENTRATION ; CAUTION SHOULD BE EXERCISED IF USED CONCURRENTLY
|
CO-ADMINISTRATION OF CELECOXIB WITH DRUGS KNOWN TO INHIBIT CYP4502C9, SUCH AS AMIODARONE, MAY RESULT IN INCREASED PLASMA CONCENTRATION ; CAUTION SHOULD BE EXERCISED IF USED CONCURRENTLY
|
CO-ADMINISTRATION OF CELECOXIB WITH DRUGS KNOWN TO INHIBIT CYP4502C9, SUCH AS AMIODARONE, MAY RESULT IN INCREASED PLASMA CONCENTRATION ; CAUTION SHOULD BE EXERCISED IF USED CONCURRENTLY
|
CO-ADMINISTRATION OF CELECOXIB WITH DRUGS KNOWN TO INHIBIT CYP4502C9, SUCH AS AMIODARONE, MAY RESULT IN INCREASED PLASMA CONCENTRATION ; CAUTION SHOULD BE EXERCISED IF USED CONCURRENTLY
|
CO-ADMINISTRATION OF CELECOXIB WITH DRUGS KNOWN TO INHIBIT CYP4502C9, SUCH AS AMIODARONE, MAY RESULT IN INCREASED PLASMA CONCENTRATION ; CAUTION SHOULD BE EXERCISED IF USED CONCURRENTLY
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION HAS RESULTED IN A TWO-FOLD INCREASE IN CELECOXIB PLASMA CONCENTRATION DUE TO INHIBITION OF CELECOXIB METABOLISM VIA P4502C9
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED STEADY-STATE LITHIUM PLASMA LEVELS
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED STEADY-STATE LITHIUM PLASMA LEVELS
|
CO-ADMINISTRATION IN PREDOMINANTLY ELDERLY PATIENTS HAS RESULTED IN INCREASES IN PROTHROMBIN TIME AND BLEEDING
|
CO-ADMINISTRATION IN PREDOMINANTLY ELDERLY PATIENTS HAS RESULTED IN INCREASES IN PROTHROMBIN TIME AND BLEEDING
|
CO-ADMINISTRATION IN PREDOMINANTLY ELDERLY PATIENTS HAS RESULTED IN INCREASES IN PROTHROMBIN TIME AND BLEEDING
|
CO-ADMINISTRATION IN PREDOMINANTLY ELDERLY PATIENTS HAS RESULTED IN INCREASES IN PROTHROMBIN TIME AND BLEEDING
|
CO-ADMINISTRATION IN PREDOMINANTLY ELDERLY PATIENTS HAS RESULTED IN INCREASES IN PROTHROMBIN TIME AND BLEEDING
|
CO-ADMINISTRATION IN PREDOMINANTLY ELDERLY PATIENTS HAS RESULTED IN INCREASES IN PROTHROMBIN TIME AND BLEEDING
|
CO-ADMINISTRATION IN PREDOMINANTLY ELDERLY PATIENTS HAS RESULTED IN INCREASES IN PROTHROMBIN TIME AND BLEEDING
|
NSAIDS INHIBIT SPREADING ACTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY CAUSE CARBACHOL INEFFECTIVE
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION
|